First New York Securities LLC NY bought a new position in Quotient Ltd. (NASDAQ:QTNT) during the second quarter, according to its most recent disclosure with the SEC. The fund bought 18,000 shares of the company’s stock, valued at approximately $140,000.
Other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC acquired a new position in shares of Quotient during the first quarter worth $105,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Quotient during the first quarter worth $172,000. Finally, Bellevue Group AG acquired a new position in shares of Quotient during the first quarter worth $880,000. Hedge funds and other institutional investors own 41.50% of the company’s stock.
Quotient Ltd. (NASDAQ:QTNT) traded down 1.00% during midday trading on Wednesday, hitting $7.89. 23,337 shares of the company were exchanged. Quotient Ltd. has a 1-year low of $5.67 and a 1-year high of $17.44. The stock’s market capitalization is $113.43 million. The stock has a 50 day moving average of $6.86 and a 200-day moving average of $8.33.
A number of brokerages have recently weighed in on QTNT. Jefferies Group restated a “buy” rating and issued a $28.00 target price on shares of Quotient in a research note on Wednesday, June 1st. Zacks Investment Research raised shares of Quotient from a “sell” rating to a “hold” rating in a report on Friday, August 12th.
In other Quotient news, insider D J. Paul E. Cowan bought 45,455 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The stock was acquired at an average price of $5.50 per share, with a total value of $250,002.50. Following the completion of the purchase, the insider now owns 26,666 shares of the company’s stock, valued at $146,663. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director L John Wilkerson bought 180,000 shares of the firm’s stock in a transaction on Wednesday, August 3rd. The shares were acquired at an average cost of $5.50 per share, with a total value of $990,000.00. The disclosure for this purchase can be found here. Company insiders own 40.50% of the company’s stock.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Want to see what other hedge funds are holding QTNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quotient Ltd. (NASDAQ:QTNT).
Receive News & Ratings for Quotient Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.